Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘JPM16’

Day 3 Highlights from JP Morgan Healthcare Conference #JPM16

San Francisco JPM16 Day 3It’s Day 3 of the JP Morgan Healthcare Conference in San Francisco, and we hope that you’re enjoying our commentary and analysis around some of the presentations & news each day. If you’re reading this and aren’t a subscriber already, then why not become one?

We’re not offering a substitute for watching a company presentation yourself, they’re freely available by webcast and several companies have also put up their presentations up on their websites, but in a world awash with information competing for time and attention, we hope we’ve teased out a few of the noteworthy points.

Yesterday, on the Day 2 post we commented on $AMGN, $RHBBY, $BMY, $SGMO, $IMGN and more.

Subscribers can login to read today’s rolling post or you can purchase access below.

Highlights of #JPM16 Healthcare Conference Day 2

San Francisco JPM16 Day 2It’s Tuesday at the 2016 JP Morgan Healthcare conference in San Francisco (Twitter #JPM16).

Each day of #JPM16 we’re doing a rolling blog post which we’re updating throughout the day with commentary and insights on the company presentations we’re covering.

While we’re not giving a blow-by-blow account, many companies have the slides readily available, we will be commenting on noteworthy news, and what we learn about corporate strategy going into 2016.

For those of you who like to catch up with the final summary of each day’s highlights, you can read yesterday’s Day 1 synopsis here and our interview with Seattle Genetics CEO, Clay Siegall here.

Subscribers can login or you can purchase access below.

error: Content is protected !!